

Figure S1 The scatter plot of MR analysis (Galectin-3 to Cervical cancer)




Figure S2 The scatter plot of MR analysis (Galectin-8 to Cervical cancer)




Figure S3 The scatter plot of MR analysis (Galectin-1 to Ovarian cancer)




Figure S4 The scatter plot of MR analysis (Galectin-9 to Ovarian cancer)




Figure S5 The scatter plot of forward MR analysis (Galectin-10 to Ovarian cancer)




Figure S6 The scatter plot of forward MR analysis (Galectin-10 to Clear cell ovarian cancer)




Figure S7 The scatter plot of MR analysis (Galectin-1 to High grade serous ovarian cancer)




Figure S8 The scatter plot of MR analysis (Galectin-1 to Invasive mucinous ovarian cancer)




Figure S9 The scatter plot of MR analysis (Galectin-9 to Invasive mucinous ovarian cancer)




Figure S10 The scatter plot of MR analysis (Galectin-2 to Malignant neoplasm of corpus uteri)




Figure S11 The scatter plot of MR analysis (Galectin-4 to Malignant neoplasm of corpus uteri)




Figure S12 The scatter plot of MR analysis (Galectin-4 to Endometrial cancer)




Figure S13 The scatter plot of MR analysis (Galectin-2 to Endometrial cancer (endometrioid histology))




Figure S14 The scatter plot of MR analysis (Galectin-4 to Endometrial cancer (endometrioid histology))




Figure S15 The scatter plot of MR analysis (Galectin-10 to Endometrial cancer (endometrioid histology))




Figure S16 MR leave-one-out sensitivity analysis of Galectin-3 to Cervical cancer




Figure S17 MR leave-one-out sensitivity analysis of Galectin-8 to Cervical cancer




Figure S18 MR leave-one-out sensitivity analysis of Galectin-1 to Ovarian cancer




Figure S19 MR leave-one-out sensitivity analysis of Galectin-9 to Ovarian cancer




Figure S20 MR leave-one-out sensitivity analysis of Galectin-10 to Ovarian cancer




Figure S21 MR leave-one-out sensitivity analysis of Galectin-10 to Clear cell ovarian Cancer




Figure S22 MR leave-one-out sensitivity analysis of Galectin-1 to High grade serous ovarian cancer




Figure S23 MR leave-one-out sensitivity analysis of Galectin-1 to Invasive mucinous ovarian cancer




Figure S24 MR leave-one-out sensitivity analysis of Galectin-9 to Invasive mucinous ovarian cancer




Figure S25 MR leave-one-out sensitivity analysis of Galectin-2 to Malignant neoplasm of corpus uteri




Figure S26 MR leave-one-out sensitivity analysis of Galectin-4 to Malignant neoplasm of corpus uteri




Figure S27 MR leave-one-out sensitivity analysis of Galectin-4 to Endometrial cancer




Figure S28 MR leave-one-out sensitivity analysis of Galectin-2 to Endometrial cancer (endometrioid histology)




Figure S29 MR leave-one-out sensitivity analysis of Galectin-4 to Endometrial cancer (endometrioid histology)




Figure S30 MR leave-one-out sensitivity analysis of Galectin-10 to Endometrial cancer (endometrioid histology)